Literature DB >> 11291830

A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies.

C D Blanke1, M Stipanov, J Morrow, M Rothenberg, R Chinery, Y Shyr, R Coffey, D H Johnson, S D Leach, R D Beauchamp.   

Abstract

Six patients with incurable malignancies were originally treated with vitamin E, 3200 IU/day for fourteen days, followed by the same dose of vitamin E daily plus LCV (20 mg/m2 i.v. bolus daily x 5) with 5FU (425 mg/m2 i.v. bolus immediately following LCV). The same schedule of LCV and 5FU was repeated 4 weeks later, then every 5 weeks indefinitely. When 3 of the first 6 had grade 3/4 toxicity, six more patients were treated on the identical drugs and schedule. Seven of twelve total patients had one or more grade 3/4 toxicities. Neutropenia, abdominal pain, and diarrhea were most common. No patient had a documented response, though seven patients did have stable disease. Though the combination of vitamin E and chemotherapy was toxic, this trial demonstrated maximal therapeutic doses of vitamin E can be combined with standard 5FU and LCV, without significantly increasing the side effects of the chemotherapy itself.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11291830     DOI: 10.1023/a:1006484031959

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  18 in total

Review 1.  Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in human cancers.

Authors:  T Byers; G Perry
Journal:  Annu Rev Nutr       Date:  1992       Impact factor: 11.848

2.  A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.

Authors:  N Petrelli; L Herrera; Y Rustum; P Burke; P Creaven; J Stulc; L J Emrich; A Mittelman
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

3.  A double-blind trial of vitamin E in angina pectoris.

Authors:  T W Anderson; D B Reid
Journal:  Am J Clin Nutr       Date:  1974-10       Impact factor: 7.045

4.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

Authors:  A de Gramont; J F Bosset; C Milan; P Rougier; O Bouché; P L Etienne; F Morvan; C Louvet; T Guillot; E François; L Bedenne
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 5.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

Authors:  M A Poon; M J O'Connell; C G Moertel; H S Wieand; S A Cullinan; L K Everson; J E Krook; J A Mailliard; J A Laurie; L K Tschetter
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

Review 6.  Isoprostanes: potential markers of oxidant stress in atherothrombotic disease.

Authors:  C Patrono; G A FitzGerald
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

7.  Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta.

Authors:  R Chinery; J A Brockman; M O Peeler; Y Shyr; R D Beauchamp; R J Coffey
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

8.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

Authors:  P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

9.  Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study.

Authors:  R C Coombes; C E Chilvers; D Amadori; F Medi; G Fountzilas; H Rauschecker; P Vassilopoulos; E P Ferreira; G Vannozzi; J M Bliss
Journal:  Ann Oncol       Date:  1994-01       Impact factor: 32.976

10.  Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress.

Authors:  J D Morrow; L J Roberts
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

View more
  1 in total

Review 1.  Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy.

Authors:  Akiko Nakayama; Karen P Alladin; Obianuju Igbokwe; Jeffrey D White
Journal:  Cancer Invest       Date:  2011-12       Impact factor: 2.176

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.